February 2012

Bristol-Myers Squibb's Orencia

February 23, 2012

New Drug Review

The FDA approved a subcutaneous formulation of Bristol-Myers Squibb's Orencia (abatacept) for the treatment of moderately to severely active rheumatoid arthritis in adults.

Are You Prepared for the ICD-10 Changes?

February 22, 2012

Washington Insights

The International Classification of Diseases codes will undergo significant changes to address the limitations of coding hospital inpatient procedures and patient medical conditions. Here's what you'll need to know to stay abreast.

Loyalty: The Measure of Value

February 21, 2012

Specialty Pharmacy Nursing

Increasing customer satisfaction leads to the likelihood of customer loyalty. Nurses can provide value-added services for specialty pharmacies, manufacturers, and payers that promote customer loyalty.

Specialty Pharmacy Management of Gout

February 20, 2012

Features

New drugs and drugs in the pipeline for gout have changed the treatment for this painful disease, one of the oldest documented diseases. Here's an update on what's new and what specialty pharmacists need to know as they counsel patients for gout.

Orphan Drugs: Small Markets, Big Opportunity

February 20, 2012

Features

Orphan drug development has taken off as this segment of the industry has seen impressive growth. Here's an expert analysis of the orphan market by an industry leader outlining the challenges and opportunities.

Specialty Pharmacy: Increasing Value Through Accountability and Collaboration

February 20, 2012

Features

This dynamic market is seeing a lot of growth, changes, and challenges. Specialty pharmacists can tackle the tough issues and raise the bar on greater levels of efficiency, accountability, and service while curtailing costs.

Managed Care Biologics and Injectables

February 17, 2012

Features

Payer response to new entrants to the multiple sclerosis (MS) market is mixed as some believe that there remain meaningful, major unmet needs in the MS category, according to The Zitter Group's Spring 2011 Managed Care Biologics and Injectables Index.